Cite

HARVARD Citation

    Signoriello, E. et al. (2016). Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis. Multiple sclerosis. pp. 921-925. [Online]. 
  
Back to record